ylliX - Online Advertising Network
Press Release

Roche’s Alzheimer’s Candidate Secures FDA Breakthrough Designation

Roche's Alzheimer's Candidate Secures FDA Breakthrough Designation

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

Roche Holdings AG’s (OTC: RHHBY) gantenerumab antibody received breakthrough therapy designation from the FDA for Alzheimer’s disease. Gantenerumab is designed to neutralize beta-amyloid plaques seen as a driver behind brain cell death.

...read full article on Benzinga

ylliX - Online Advertising Network